All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Snakebite envenoming is a neglected disease *par excellence* that primarily affects poor communities in the tropics, but attracts little interest from pharmaceutical companies, health agencies and research funding bodies. This neglect has resulted in a paucity of scientific evidence on which to base therapeutic decisions and support robust guidelines. The antivenom development pipeline remains desperately dry \[[@pntd.0005612.ref001],[@pntd.0005612.ref002]\]. Moreover, the absence of rigorous regulatory oversight has resulted in the marketing of antivenom of doubtful efficacy and variable quality and safety \[[@pntd.0005612.ref001]--[@pntd.0005612.ref003]\]. The optimal dosage of antivenom is highly debated. Antivenom potency varies widely, and the initial doses recommended by manufacturers range from 1 to over 30 vials \[[@pntd.0005612.ref004]\]. Recommendations are usually based on median lethal (LD~50~) and effective dose (ED~50~) assays in which venom and antivenom are incubated *in vitro* before being injected into mice. However, rodent models are poor substitutes for clinical trials \[[@pntd.0005612.ref005]\], and few randomised, dose ranging controlled trials (RCT) of snakebite envenoming have been conducted \[[@pntd.0005612.ref006]--[@pntd.0005612.ref016]\]. Moreover, a recent systematic review found that trials conducted in South Asia generated very low quality evidence \[[@pntd.0005612.ref017]\].

In Nepal, snakebite is an important public health problem \[[@pntd.0005612.ref018]--[@pntd.0005612.ref020]\] with peak annual incidence and mortality rates of up to 1162/100 000 and 162/100 000, respectively, reported in eastern regions \[[@pntd.0005612.ref019]\]. Snakebite is a disease of poverty. Farmers, plantation workers and herders are the main victims \[[@pntd.0005612.ref021]\]. Elapid snakes, notably the Indian spectacled cobra (*Naja naja*) and the common krait (*Bungarus caeruleus*), cause most cases of snakebite envenoming in Nepal \[[@pntd.0005612.ref022],[@pntd.0005612.ref023]\]. Elapid envenoming is characterized by a progressive, descending neuromuscular paralysis, leading to respiratory failure and death \[[@pntd.0005612.ref024],[@pntd.0005612.ref025]\]. Since 1998, Indian polyvalent antivenom has been provided free of charge to all hospitals in Nepal by the Ministry of Health (MoH). The treatment of envenoming varies widely, with antivenom total doses ranging from 2 to 115 vials \[[@pntd.0005612.ref018]\]. Case fatality rates (CFR) also vary widely, from 3% to 58% \[[@pntd.0005612.ref018]\].

Indian polyvalent antivenom costs between 6·50 to 11·00 US\$ per vial \[[@pntd.0005612.ref026]\]. In order to minimise expense, the Nepalese MoH recommends a low initial dose (2 vials) of antivenom as an intravenous (IV) push, followed by an infusion of additional vials titrated to clinical response \[[@pntd.0005612.ref027]\], consistent with some manufacturer guidelines. However, this dosing regimen contrasts with expert opinion which recommends a high loading dose of 10 vials (100 ml) administered as an IV push, arguing that this should neutralize neurotoxins more effectively before they become irreversibly bound to tissue receptors \[[@pntd.0005612.ref028],[@pntd.0005612.ref029]\]. World Health Organization (WHO) guidelines also recommend an initial dose of 10 vials for envenoming after bites by South Asian cobras and kraits \[[@pntd.0005612.ref030]\]. There are no published RCTs addressing the optimal dose of antivenom in neurotoxic envenoming and observational studies are unhelpful \[[@pntd.0005612.ref031],[@pntd.0005612.ref032]\]. Given the lack of data and the need to optimise treatment of snakebite envenoming in Nepal, we conducted an RCT comparing high versus low initial antivenom dose in patients with neurotoxic envenoming.

Methods {#sec006}
=======

Ethics statement {#sec007}
----------------

Ethical approvals were obtained from the B.P. Koirala Institute of Health Sciences Ethics Committee, the Nepal Health Research Council (NHRC) and the Geneva University Hospitals Ethics Committee. The study was registered on clinicaltrials.gov (NCT01284855). Written informed consent was obtained from all adult participants prior to inclusion, and from guardians for minor participants. Whenever possible assent was also sought from children. For participants who were unable to read and/or write, an independent witness was present during the consent process and signed the consent form next to the participant's thumbprint.

Study design {#sec008}
------------

This was a balanced, randomised, double-blind, parallel trial comparing two dosing regimens of antivenom. The study was conducted between April 2011 and March 2013 at the Snake Bite Treatment Centre of Damak Red Cross Society, the Snake Bite Management Centre of Charali, both in Jhapa district, and the Bharatpur District Hospital, Bharatpur, in Chitwan district. All centres are located in the Terai plains of Nepal.

Participants {#sec009}
------------

Snakebite victims were enrolled in the study if they gave written informed consent (assent if aged 12 to 18) and had ≥1 sign(s) of neurotoxic envenoming: bilateral ptosis; inability to frown, open the mouth, protrude the tongue, or clear secretions; broken neck sign; skeletal muscle weakness (power \< 3 UK MRC scale); gag reflex loss; and paradoxical breathing.

Those presenting \>24 hours post-bite, with a proven viper bite, who had already received antivenom, or were children below 5 years, pregnant or breast feeding women, individuals with a history of neuromuscular disease, known allergy to horse protein, and those with an immediate need for mechanical ventilation were excluded.

Randomisation and masking {#sec010}
-------------------------

Randomisation was stratified by centre, and within each stratum, patients were randomized in blocks of variable sizes, according to a computer generated list. Sealed sequentially numbered envelopes containing the antivenom regimen were prepared accordingly. For quality control, 10% of the envelopes were double-checked by an independent statistician.

The envelopes were kept in the site pharmacy, to which only the trial pharmacist had access. Upon inclusion of a trial participant, the pharmacist opened the envelope in sequence. Reconstitution of antivenom, dilution and preparation of push injections and perfusions took place in the pharmacy. To maintain blinding, the total volume and appearance of push injections and infusions were identical in the two study arms. The study clinicians and patients were unaware of treatment allocation. If neurotoxicity persisted or worsened, the clinician asked the pharmacist to prepare additional doses of antivenom, according to the indications found in the randomisation envelope for that patient. This was done in the same concealed manner. Compliance with randomisation and masking procedures was assessed as part of the GCP monitoring of the trial.

Intervention and trial procedures {#sec011}
---------------------------------

We used two batches of lyophilised polyvalent antivenom raised against Indian *Daboia russelii*, *Echis carinatus*, *Bungarus caeruleus* and *Naja naja* venoms, manufactured by VINS Bioproducts Ltd, Hyderabad, India. The neutralizing potency of the antivenom (mg of Indian snake venom neutralized per mL of antivenom) as stated by the manufacturer in the Certificate of Analysis (CoA) was: 0.681 mg and 0.636 mg for *N*. *naja*, 0.541 mg for *B*. *caeruleus*, 0.704 mg for *D*. *russelii*, and 0.612 mg and 0.616 mg for *E*. *carinatus*. Trial participants received either the dose regimen recommended by the Nepalese national protocol (low initial dose group) or a high initial dose as recommended by WHO guidelines (high initial dose group). The low initial dose regimen consisted of an initial dose of 2 vials given by IV push, followed by the infusion of 4 vials over 4 hours. If signs of envenoming persisted after the initial 4 hours, the 4 vial infusion was repeated up to three times. If signs of envenoming persisted after 12 hours, an infusion of 2 vials of antivenom was given over 4 hours, every 4 hours, until recovery. In the case of neurotoxic deterioration, 2 vials were administered by IV push as recommended by national guidelines. To maintain the blinding, the high initial dose regimen was adapted to the administration method used in the low initial dose arm. It consisted of an initial dose of 2 vials given by IV push followed by an 8 vial infusion over one hour and an infusion of saline over 3 hours. If signs of envenoming persisted after these first 4 hours, the saline infusion was repeated, to mimic the infusion given in the low initial dose arm. In the case of deteriorating neurotoxic signs, 5 vials of antivenom were given by IV push. The two regimens are described in [S2 Fig](#pntd.0005612.s002){ref-type="supplementary-material"}. The total number of vials of antivenom administered was restricted to 30, irrespective of treatment allocation.

Patients were hospitalised throughout the treatment period. After initial dosing, clinical evaluation was performed every hour until full recovery. Anaphylaxis was managed by stopping the antivenom immediately and administering intramuscular (IM) adrenaline, IV hydrocortisone and IV chlorphenamine. Oxygen, salbutamol inhalations, or the rapid administration of normal saline were given as indicated clinically. Following the publication of an RCT showing the benefits of subcutaneous adrenaline premedication \[[@pntd.0005612.ref033]\], we adopted this strategy after April 2012.

Three follow-up visits were scheduled to assess short and medium-term patient outcome: 7 days, 21 days and 6 months after hospital discharge.

Outcomes {#sec012}
--------

The primary effectiveness endpoint was a combination of (a) in-hospital death, (b) the need for assisted ventilation and (c) worsening or recurrence of neurotoxicity after the initial dose of antivenom.

The clinical indications for intubation and assisted ventilation were (1) absent gag reflex, (2) presence of paradoxical breathing, (3) respiratory distress or cyanosis, whichever was detected first, and/or (4) oxygen saturation \<90% despite high flow oxygen supplementation.

The primary composite endpoint was evaluated at each clinical evaluation, i.e., every hour until full recovery from neurotoxic envenoming. If a patient presented at least one of the sub-criteria, the primary endpoint was deemed positive. If all the sub-criteria were indicated as being absent until full recovery, the primary composite endpoint was deemed negative. Patients with missing data in one of the sub-criteria always presented with at least one other sub-criterion, enabling us to define presence of the primary composite outcome for all patients.

Secondary endpoints included time to recovery and number of antivenom vials used. The safety endpoints were incidence of adverse events (AEs) and serious adverse events (SAEs).

The evolution of neurotoxicity was assessed by a scoring method ([S1 Fig](#pntd.0005612.s001){ref-type="supplementary-material"}). Worsening of neurotoxicity was defined as (1) appearance of ≥ 2 new signs, or (2) appearance of one severe sign (i.e., loss of gag reflex or paradoxical breathing). Persistence of neurotoxicity was defined as the persistence of ≥ 1 sign/s in the absence of criteria of neurotoxicity worsening. Patients were assessed hourly until signs of neurotoxicity disappeared (i.e., clinical score = 0). Complete neurological recovery was defined as reaching and sustaining a score of 0.

Dead snakes brought by victims were labelled and preserved in ethanol. Blinded identification was conducted by taxonomic experts. Morphological features of snakes and mitochondrial cytochrome b sequences of snakes generated using trace DNA swabbed from bite sites were analysed by comparison with reference specimens in museum collections and existing nucleotide sequence databases \[[@pntd.0005612.ref023]\].

Sample size, and statistical analyses {#sec013}
-------------------------------------

We assumed a 60% rate of the composite primary outcome in the low dose group, and hypothesised that this would be reduced to 40% in the high dose group. Therefore, 99 patients would be needed in each arm (1-β = 80%, two-sided α = 0·05) and, assuming a dropout rate of 20%, the total estimated sample size was 250 patients.

Effectiveness and safety analyses were performed on a modified intention-to-treat (mITT) population, i.e., all patients who received antivenom and had at least one post-baseline effectiveness evaluation. Analyses were also performed on a per-protocol (PP) population to support conclusions made using the mITT population. The PP population was defined by comparing the total dose of antivenom that participants should have received based on the treatment allocation and their clinical evolution, to the actual total dose administered.

We described patients' baseline characteristics overall and per treatment arm as frequencies for categorical data and median and inter-quartile ranges (IQR) or means and standard deviations (SD), as appropriate, for continuous data.

Categorical data were compared using Chi-squared or Fisher's exact test, as appropriate. Continuous data were compared using the Student t or the Mann Whitney U tests.

Survival analyses were conducted (1) on the time free from primary endpoint; (2) on the time to reach a neurotoxicity score of 0. For the latter, fatal cases were included and considered as having never recovered. Survival estimates were obtained with the Kaplan-Meier estimator and the comparison between groups was performed using a log-rank test stratified by center. Adverse Events (AEs) were compared between treatment arms using Fisher's exact test. All AEs were coded using the MedDRA dictionary version 17·0.

Except for the safety endpoints (AEs and SAEs) for which missing values were considered as no events, no missing data imputation was used.

A two-sided p value ≤ 0·05 was considered statistically significant for all analyses. All analyses were performed on R software (R foundation for Statistical Computing, Vienna, Austria, URL <http://www.Rproject.org>).

Results {#sec014}
=======

Between April 2011 and October 2012, we assessed 194 snakebite victims with signs of envenoming, of whom 157 were enrolled into the trial (patient flow shown in [Fig 1](#pntd.0005612.g001){ref-type="fig"}). Of these, 78 and 79 were randomised to the low and high initial dose groups, respectively. Two participants did not receive antivenom because one died before antivenom could be started, and the other had been wrongly randomised (absence of neurotoxicity). One patient in the high dose group withdrew consent. Finally, 154 patients could be included in the mITT analysis while 137 patients were included in the PP analysis.

![Flow diagram of the progress of participants through the parallel, randomized trial of high initial dose versus low initial dose of snake antivenom for the treatment of neurotoxic envenoming.](pntd.0005612.g001){#pntd.0005612.g001}

The two treatment groups were similar with respect to baseline characteristics and sex ratio ([Table 1](#pntd.0005612.t001){ref-type="table"}). Thirty-two patients out of 154 (20·8%) were aged \< 15 years. The severity of envenoming on admission was similar in both groups. The snake species was identified in 53 (34·4%) of 154 trial participants: 29 had been bitten by spectacled cobras (*Naja naja*), 20 by common kraits (*Bungarus caeruleus*), two by other kraits (*B*. *lividus* and *B*. *niger*), and two by other cobras (*Naja kaouthia* and *Naja* sp.). The distribution of snake species was balanced between treatment groups. Kraits caused more bites in Bharatpur than Damak (see [S1 Table](#pntd.0005612.s004){ref-type="supplementary-material"}).

10.1371/journal.pntd.0005612.t001

###### Baseline demographic and epidemiological characteristics of trial participants.

Figures are numbers of participants (percentage) unless stated otherwise.

![](pntd.0005612.t001){#pntd.0005612.t001g}

  Parameter                                      Overall N = 154   Low dose N = 76   High dose N = 78
  ------------------------------- -------------- ----------------- ----------------- ------------------
  Study Center                    Damak          55 (35·7%)        27 (35·5%)        28 (35·9%)
  Charali                         26 (16·9%)     12 (15·8%)        14 (18·0%)        
  Bharatpur                       73 (47·4%)     37 (48·7%)        36 (46·2%)        
  Sex                             Female         80 (51·9%)        39 (51·3%)        41 (52·6%)
  Male                            74 (48·1%)     37 (48·7%)        37 (47·4%)        
  Age (years)                     Median (IQR)   28 (16--46)       26 (16--44)       32 (17--49)
  Time to reach center (min)      Median (IQR)   75 (45--148)      66 (41--134)      80 (50--150)
  *Missing*                       *7*            *2*               *5*               
  Neurotoxic score on admission   Mean ± sd      2·14 ± 1·18       2·21 ± 1·33       2·08 ± 1·01
  Snake species                   Unidentified   101 (65·6%)                         
  Identified                      53 (34·4%)                                         
  Cobra                           31 (58%)       15 (58%)          16 (59%)          
  Krait                           22 (42%)       11 (42%)          11 (41%)          

Of the 154 participants included in the mITT analysis, 67 (43·5%) participants met the primary composite outcome definition of death, need for ventilation or worsening of neurotoxicity ([Table 2](#pntd.0005612.t002){ref-type="table"}). The proportion was slightly higher in the low vs. high initial dose group but this difference was not statistically significant (risk difference = 10·2%, 95%CI \[-6·7; 27·1\], p = 0·264). The proportions of patients who either died, required assisted ventilation or experienced worsening neurotoxicity did not differ among treatment groups. In a similar way, neither the time to primary outcome (HR = 0·72 95%CI \[0·45; 1·17\], p = 0·20) nor the time to recovery (HR = 1·13 95%CI \[0·79; 1·63\], p = 0·50) was significantly different between the two groups ([Fig 2A and 2B](#pntd.0005612.g002){ref-type="fig"}). Similar results were obtained in the PP analysis (HR = 0·62 95%CI \[0·37; 1·05\], p = 0·07 and HR = 1·38 95%CI \[0·94; 2·02\], p = 0·17, respectively) and in a per centrer analysis (see [S2 Table](#pntd.0005612.s005){ref-type="supplementary-material"} and [S3 Fig](#pntd.0005612.s003){ref-type="supplementary-material"}).

10.1371/journal.pntd.0005612.t002

###### Effectiveness endpoints in modified intention-to-treat population.

Figures are numbers of participants (percentage) unless stated otherwise.

![](pntd.0005612.t002){#pntd.0005612.t002g}

                                                              Low dose     High dose    Risk difference \[95%CI\]                                    p-value   HR[\*](#t002fn002){ref-type="table-fn"} \[95%CI\]   p-value[\*\*](#t002fn003){ref-type="table-fn"}
  ----------------------------------------------------------- ------------ ------------ ------------------------------------------------------------ --------- --------------------------------------------------- ------------------------------------------------
  Primary composite outcome                                   37 (48·7%)   30 (38·5%)   10·2% \[-6·7; 27·1\]                                         0·264     0·72\[0·45; 1·17\]                                  0·199
   Worsening toxicity[^1^](#t002fn001){ref-type="table-fn"}   31 (43·7%)   27 (35·5%)   8·1% \[-9·0; 25·3\]                                          0·401                                                         
   Need for ventilation                                       15 (19·7%)   13 (16·7%)   3·1% \[-10·4; 16·6\]                                         0·776                                                         
   Death                                                      2 (2·6%)     7 (9·0%)     -6·3% \[-14·9; 2·2\]                                         0·167                                                         
  Number of vials, mean ± sd                                  11·0 ± 7·9   12·5 ± 3·9   1·5 \[-0·5; 3·5\][\*\*\*](#t002fn004){ref-type="table-fn"}   0·142                                                         
   \< 10 vials                                                41 (53·9%)   0 (0%)                                                                                                                                  
   10 to 15 vials                                             17 (22·4%)   70 (89·7%)                                                                                                                              
   \> 15 vials                                                18 (23·7%)   8 (10·3%)                                                                                                                               

^1^Seven patients had missing data for neurotoxicity score, 5 in the low dose group and 2 in the high dose group. All of these patients required ventilation so that a positive response to the primary composite outcome could be defined. It follows that no missing data remained for the primary composite outcome.

\*adjusted for center;

\*\*log-rank test stratified for center;

\*\*\*mean difference \[95%CI\], p value from a Welch t test

![Cumulative incidence by study arm for primary outcome^1^ (left panel) and recovery^2^ (right panel) obtained with Kaplan-Meier survival estimator in 154 patients (modified intent-to-treat population).](pntd.0005612.g002){#pntd.0005612.g002}

The observed average number of vials consumed was higher in the high initial dose group (mean = 12·5) than in the low initial dose group (mean = 11·0), but the mean difference was not statistically significant (mean difference = 1·5 95%CI \[-0·5; 3·5\], p = 0·14). However, the percentage of patients having 16 or more vials was higher in the low initial dose group (24% vs. 10%, p = 0·0446) ([Table 2](#pntd.0005612.t002){ref-type="table"}).

We investigated the impact of the biting species on the effectiveness outcomes in the 53 patients for whom the species could be identified ([Table 3](#pntd.0005612.t003){ref-type="table"}). Patients bitten by kraits met the primary outcome more frequently, received more vials, recovered less often and when they did, the time for recovery was longer. The small number of victims for which the snake species could be identified precluded an effectiveness analysis by treatment group.

10.1371/journal.pntd.0005612.t003

###### Effectiveness endpoints by biting species.

![](pntd.0005612.t003){#pntd.0005612.t003g}

  -----------------------------------------------------------------------------------------------------------------------
  Snake species                                       Cobras\     Kraits (3 species)\   Difference \[95%CI\]   p-value
                                                      N = 31      N = 22                                       
  --------------------------------------------------- ----------- --------------------- ---------------------- ----------
  Primary composite outcome, N (%)                    8 (26%)     15 (68%)                                     0·004

  Patients reaching full neurotoxic recovery, N (%)   29 (94%)    9 (41%)                                      \<0·001

  Time (h) to recovery, mean ± sd                     5·0 ± 6·0   18·3 ± 12·0                                  0·0102

  Number of vials, mean ± sd                          8·9 ± 3·3   18·3 ± 6·8            9·4 \[6·2; 12·6\]      \<0·0001
  -----------------------------------------------------------------------------------------------------------------------

We also investigated the impact of the study centre on the effectiveness outcomes and found that the time to primary outcome was significantly shorter in Bharatpur than Damak, after adjustment for treatment arm (HR = 2·00 95%CI \[1·2; 3·6\], p = 0·014). The average number of vials consumed per patient was also higher in Bharatpur compared to the other two centers (mean difference = 3·7, 95%CI \[1·8; 5·6\], p = 0·0003).

A total of 137 patients (89%) reported ≥ 1 AE ([Table 4](#pntd.0005612.t004){ref-type="table"}) with no significant difference between high 73/78 (94%) and low dose 64/76 (84%) groups (risk difference = 9·4% 95%CI \[-1·8; 20·5\], p = 0·075). In 82 patients (53·2%) the AE was deemed related to antivenom treatment with no difference between high 42/78 (54%) vs. low dose 40/76 (53%) groups (p = 1). Seven out of 154 patients (5%) reported symptoms consistent with serum sickness (i.e., arthralgia occurring more than 7 days after antivenom treatment). In the PP analysis the proportion of patients experiencing at least one AE was higher in the high dose group (risk difference = 12·9% 95%CI \[-0·6; 25·2\], p = 0·0373). This difference in proportion was not specific to one type of AE. Among the 154 patients included in the mITT analysis, 18 experienced at least one SAE ([Table 5](#pntd.0005612.t005){ref-type="table"}), seven (9%) in the low dose group and 11 (14%) in the high dose group (p = 0·45). Among a total of 19 SAEs, seven were deemed definitely or probably related to the antivenom, two in the low dose group and five in the high dose group.

10.1371/journal.pntd.0005612.t004

###### Safety endpoints.

Figures are numbers of participants (percentage) unless stated otherwise.

![](pntd.0005612.t004){#pntd.0005612.t004g}

                                                        All (n = 154)   Low dose (n = 76)   High dose (n = 78)   p-value
  ----------------------------------------------------- --------------- ------------------- -------------------- ---------
  Patients reporting Adverse Events                     137 (89%)       64 (84%)            73 (94%)             0·075
  Patients reporting Serious Adverse Events             18 (12%)        7 (9%)              11 (14%)             0·45
  Type of events reported                                                                                        
  *Skin and subcutaneous tissue disorders*              101 (65·6%)     49 (64·5%)          52 (66·7%)           0·866
   Infected bite                                        62 (61·4%)      34 (44·7%)          28 (35·9%)           0·324
   Pruritus, rash or angioedema                         59 (58·4%)      29 (38·2%)          30 (38·5%)           1
  *General disorders*                                   75 (48·7%)      35 (46·1%)          40 (51·3%)           0·524
   Fever and chills                                     73 (47·4%)      35 (46·1%)          38 (48·7%)           0·750
  *Gastrointestinal disorders*                          51 (33·1%)      28 (36·8%)          23 (29·5%)           0·393
   Epigastric discomfort                                28 (18·2%)      16 (21·1%)          12 (15·4%)           0·408
   Vomiting                                             23 (14·9%)      11 (14·5%)          12 (15·4%)           1
   Abdominal pain                                       6 (3·9%)        4 (5·3%)            2 (2·6%)             0·439
  *Respiratory*, *thoracic and mediastinal disorders*   39 (25·3%)      18 (23·7%)          21 (26·9%)           0·712
   Tachypnoea                                           24 (15·6%)      10 (13·2%)          14 (17·9%)           0·507
   Wheezing/laryngeal edema                             13 (8·4%)       7 (9·2%)            6 (7·7%)             0·779
   Respiratory failure                                  6 (3·9%)        0 (0%)              6 (7·7%)             0·028
  *Nervous system disorders*                            22 (14·3%)      8 (10·5%)           14 (17·9%)           0·250
   Paraesthesia                                         11 (7·1%)       6 (7·9%)            5 (6·4%)             0·764
   Headache                                             7 (4·5%)        1 (1·3%)            6 (7·7%)             0·117
  *Musculoskeletal and connective tissue disorders*     22 (14·3%)      9 (11·8%)           13 (16·7%)           0·491
   Myalgia                                              9 (5·8%)        3 (3·9%)            4 (5·1%)             1
   Arthralgia[^1^](#t004fn001){ref-type="table-fn"}     7 (4·5%)        3 (3·9%)            4 (5·1%)             1

^1^ Late arthralgia: defined as occurring later than 7 days after treatment initiation

10.1371/journal.pntd.0005612.t005

###### List of serious adverse events (SAE) occurring in snakebite victims with neurotoxic signs randomized to either a low or a high initial dose of antivenom.

![](pntd.0005612.t005){#pntd.0005612.t005g}

       Nature of the SAE                                    Seriousness criteria                                 Relationship to treatment   Outcome
  ---- ---------------------------------------------------- ---------------------------------------------------- --------------------------- ------------------------
  1    Anaphylactic reaction                                Life-threatening                                     Definitely related          Resolved
  2    Anaphylactic reaction                                Results in death                                     Probably related            Death
  3    Anaphylactic reaction                                Life-threatening                                     Definitely related          Resolved
  4    Delayed anaphylactic reaction                        Results in death                                     Probably related            Death
  5    Anaphylactic reaction                                Life-threatening                                     Definitely related          Resolved
  6    Anaphylactic reaction                                Life-threatening                                     Definitely related          Resolved
  7    Gangrene of bitten finger                            Prolonged hospitalization and permanent disability   Unlikely to be related      Resolved with sequelae
  8    Respiratory failure                                  Results in death                                     Not related                 Death
  9    Cardiac arrest                                       Life-threatening                                     Definitely related          Resolved
  10   Tracheostomy[^1^](#t005fn001){ref-type="table-fn"}   Results in death                                     Unlikely to be related      Not resolved
  11   Sudden death after discharge (unexplained)           Results in death                                     Unlikely to be related      Not resolved
  12   Anaphylactoid reaction                               Life-threatening                                     Probably related            Resolved
  13   Overdose[^2^](#t005fn002){ref-type="table-fn"}       Overdose                                             NA                          NA
  14   Death (unexplained reason)                           Results in death                                     Unlikely to be related      Death
  15   Death (overwhelming envenoming)                      Results in death                                     Unlikely to be related      Death
  16   Post-anoxic myoclonus                                Prolonged hospitalization                            Unlikely to be related      Recovered
  17   Anaphylactoid reaction                               Results in death                                     Probably related            Death
  18   Respiratory failure                                  Results in death                                     Unlikely to be related      Death
  19   Death (overwhelming envenomation)                    Results in death                                     Unlikely to be related      Death

^1^Death consecutive to tracheostomy occurred in the same patient as the cardiac arrest.

^2^As per trial protocol, overdose of antivenom were to be considered as SAE and reported on expedited basis to the sponsor.

The incidence of anaphylactic reactions did not differ significantly before and after the implementation of the low-dose adrenaline pre-treatment in April 2012 (pruritus, rash or angiodema: 30/85 (35·3%) vs. 29/69 (42·0%) p = 0·491, wheezing/laryngeal oedema 10/85 (11·8%) vs. 3/69 (4·3%) p = 0·175, anaphylaxis 0/85 (0%) vs. 1/69 (1·5%) p = 0·448, cardiovascular shock 4/85 (4·7%) vs. 0/69 (0%) p = 0·128).

Discussion {#sec015}
==========

This study failed to demonstrate that a high initial dose of antivenom was more effective than a low initial dose in treating neurotoxic envenoming among Nepali patients. None of the components of the composite primary end point were significantly different in the higher dose group, but the data suggested that the rate of progression was slower in this group. The occurrence of AEs appeared slightly higher in the high dose group (statistical significance was not achieved in mITT but in PP analyses), however this difference was not clinically relevant.

Our study took place in two dedicated snakebite clinics, one in a rural area and the other in a small town, and in a referral hospital of a larger town. Thus, our study mirrored the routine management of snakebite victims in Nepal and, probably, most of South Asia. This and the low number of losses-to-follow-up increased our study's external validity. Another significant strength was the ability to ascertain the biting species in a third of patients. Identifying the snake species is extremely challenging in South Asia because of the lack of robust methods \[[@pntd.0005612.ref023]\], while patients' descriptions are unreliable. The response to antivenom is highly dependent on the toxins of the biting snake. Thus, determining the biting species is key to giving the correct antivenom and anticipating the clinical course and potential complications. Other studies have achieved higher rates of species identification \[[@pntd.0005612.ref012],[@pntd.0005612.ref013]\], thanks to ELISA-based methods against circulating venom components.

To our knowledge, this is the first robust RCT to compare different dose regimens of antivenom in the treatment of neurotoxic envenoming. Most published studies lacked a proper power calculation \[[@pntd.0005612.ref007],[@pntd.0005612.ref010],[@pntd.0005612.ref034]\], were un-blinded \[[@pntd.0005612.ref007],[@pntd.0005612.ref009],[@pntd.0005612.ref010]\] and/or used inappropriate or incomplete randomization \[[@pntd.0005612.ref010],[@pntd.0005612.ref012],[@pntd.0005612.ref034]\]. Moreover, several studies mixed neurotoxic and haematotoxic envenoming or included patients with nonspecific manifestations like confusion or bradycardia \[[@pntd.0005612.ref007]--[@pntd.0005612.ref009]\]. A systematic review in 2015 deemed these studies to be of very low quality evidence \[[@pntd.0005612.ref017]\]. There is currently no validated and internationally recommended protocol to monitor the clinical progression of neurotoxic envenoming. We developed a scoring system, based on objective, readily-assessable, clinical signs that may be used by staff in small health posts or clinics. Although it has yet to be formally validated, the intra- and inter- observer reliability of the scoring method was tested during the planning phase of the trial and found to be high. The calculated scores also showed consistency across different observers and over different time periods in retrospective analysis, adding confidence to our endpoint measurements.

Almost half of the trial participants either died, developed respiratory paralysis, or experienced a worsening of neurotoxicity despite the administration of antivenom. Antivenom effectiveness depends on its ability to neutralise the venom of the local snakes. Several medically-important snake species in Nepal are not covered covered by the Indian antivenom, while *E*. *carinatus* is not present in the country \[[@pntd.0005612.ref023]\]. Although most species responsible for envenoming bites in the present study were the same as those whose venom is used to raise Indian antivenom, venom composition is known to vary within a species from region to region. The pre-clinical efficacy of Indian antivenoms against the venoms of Nepali neurotoxic species is unknown. Both the greater species diversity and geographical variation in venom composition could have contributed to the overall poor performance of the antivenom. Moreover, the utility of antivenom in the management of krait envenoming has long been questioned \[[@pntd.0005612.ref035],[@pntd.0005612.ref036]\]. The most lethal neurotoxins of krait venoms, β-bungarotoxins, are presynaptic in their mode of action, irreversibly destroying motor nerve terminals. Thus, clinical recovery is slow because it depends on the regeneration of the neuromuscular junction \[[@pntd.0005612.ref036]\]. Results of our subgroup analyses confirmed that, compared to the cobra victims, patients bitten by kraits deteriorated more frequently, recovered more slowly and required more vials of antivenom. These findings are consistent with the observation that, in Bharatpur hospital where krait bite envenoming predominates \[[@pntd.0005612.ref023]\], patients had a worse prognosis than at the other study sites. We support calls for the establishment of regional venom banks of geographically representative snake populations \[[@pntd.0005612.ref037]\] for the development of new, better-targeted antivenoms. It is also an essential pre-requisite of national regulatory authorities to test independently the effectiveness of marketed antivenoms, in line with WHO recommendations \[[@pntd.0005612.ref005]\].

The absence of a significant difference between the high and the low-dose groups in the response to antivenom should not be interpreted as evidence of no benefit of a high initial dose. This absence of statistical significance is potentially due to a lack of power owing to a lower-than-targeted sample size, an optimistic hypothesized difference in the sample size calculation (the observed difference was only \~10% whereas we powered the study to detect a 20% difference), and the substantial proportion of krait bite envenoming in our study population. Convincing evidence of the benefit or superiority of the higher initial dose regimen would require a large study with a mortality endpoint and higher proportion of identified snakes, a very unlikely scenario for such a neglected disease. In view of the complexity of the dosing regimen recommended in the Nepal national guidelines, and since a high initial dose regimen does not result in a higher consumption of antivenom, the dose regimen recommended by WHO guidelines seems a reasonable preference for treating neurotoxic envenoming in Nepal and the rest of South Asia. Clinicians will have to balance the simplicity of administration of this regimen with a slight increase in the occurrence of adverse events.
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###### Neurotoxicity score used in the trial.

Each sign scored one.
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###### Schematic diagram of antivenom dosing schedule used in the trial.
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###### Cumulative incidence by study arm and by centre for primary outcome obtained with Kaplan-Meier survival estimator in 137 patients (per protocol population).
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###### Distribution of snake species responsible for bites among study centers.
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###### Efficacy endpoints in modified per protocol population.

Figures are numbers of participants (percentage) unless stated otherwise.
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